Repligen | RGEN - Loan Capital


Repligen reported $546.58M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agilent USD 3.05B 0 Dec/2025
Align Technology USD 0 0 Dec/2024
Bio Techne USD 200M 60M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Bruker USD 1.66B 189.6M Mar/2026
Charles River Laboratories USD 2.66B 526.77M Mar/2026
Danaher USD 17.56B 855M Mar/2026
Dentsply International USD 2.01B 9M Mar/2026
General Electric Aerospace USD 18.17B 634M Mar/2026
Henry Schein USD 2.33B 17M Mar/2026
Illumina USD 1.49B 0 Mar/2026
IQVIA Holdings USD 13.99B 105M Mar/2026
Mettler Toledo International USD 2.16B 73.35M Mar/2026
Myriad Genetics USD 120.3M 400K Mar/2026
OraSure Technologies USD 100K 17K Dec/2025
Pacific Biosciences Of California USD 645.38M 223K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Repligen USD 546.58M 4.37M Mar/2026
Revvity USD 2.63B 836K Mar/2026
Standard Biotools USD 299K 0 Dec/2025
Thermo Fisher Scientific USD 40.07B 4.22B Mar/2026
Waters USD 5.22B 3.81B Mar/2026
West Pharmaceutical Services USD 202.8M 0 Mar/2026